Biomarker & Intervention Discovery

Deep Vein Thrombosis / Pulmonary Embolism (VTE)

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Spontaneous remissionWithout anticoagulation: DVT progresses to PE in 30-50%; massive PE has 30%+ mortality without treatment; spontaneous…
Best-intervention remissionDOACs (rivaroxaban, apixaban): equal or superior efficacy to warfarin with 50% reduction in major bleeding…
Gap sizeModerate — DOACs have largely replaced warfarin; remaining gap is in chronic anticoagulation decision-making and…
Primary barrierpractice
Full remission profile →

Remission & chronicity

Spontaneous remission
Without anticoagulation: DVT progresses to PE in 30-50%; massive PE has 30%+ mortality without treatment; spontaneous resolution of small PE in 30-40% but recurrence risk high
Best-intervention remission
DOACs (rivaroxaban, apixaban): equal or superior efficacy to warfarin with 50% reduction in major bleeding; catheter-directed thrombolysis for large DVT: rapid thrombus resolution but unclear long-term benefit on PTS (ATTRACT trial); acute massive PE with hemodynamic compromise: systemic thrombolysis reduces mortality 55-65%
Gap size
Moderate — DOACs have largely replaced warfarin; remaining gap is in chronic anticoagulation decision-making and post-VTE care
Primary barrier
practice
DOAC superiority is established but warfarin persistence remains common in patients with mechanical valves (where DOACs are contraindicated) and in some LMIC settings; duration of anticoagulation after unprovoked VTE is an individualised decision poorly standardised; post-thrombotic syndrome (PTS) prevention with compression is rarely implemented
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-06.

No recent clinical trials found on ClinicalTrials.gov for this condition.


Agents Found By Disease-Level Search

Searched directly from “Deep Vein Thrombosis / Pulmonary Embolism (VTE)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 0-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.